Thromb Haemost 2015; 113(06): 1278-1288
DOI: 10.1160/TH14-09-0771
Coagulation and Fibrinolysis
Schattauer GmbH

Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation

Sara J. Henderson
1   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
2   Department of Biochemistry and Biomedical Science, McMaster University, Hamilton, Ontario, Canada
,
Alan R. Stafford
1   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
3   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Beverly A. Leslie
1   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
3   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Paul Y. Kim
1   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
3   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Nima Vaezzadeh
1   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
4   Department of Medical Sciences, McMaster University, Hamilton, Ontario, Canada
,
Ran Ni
1   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
4   Department of Medical Sciences, McMaster University, Hamilton, Ontario, Canada
,
James C. Fredenburgh
1   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
3   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
,
Jeffrey I. Weitz
1   Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada
2   Department of Biochemistry and Biomedical Science, McMaster University, Hamilton, Ontario, Canada
3   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
4   Department of Medical Sciences, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Financial support: This work was supported in part by the Canadian Institutes of Health Research and the Heart and Stroke Foundation. J.I.W. holds the Heart and Stroke Foundation J. Fraser Mustard Endowed Chair in Cardiovascular Research and the Canada Research Chair (Tier 1) in Thrombosis.
Further Information

Publication History

Received: 15 September 2014

Accepted after major revision: 15 January 2015

Publication Date:
22 November 2017 (online)

Summary

Zinc circulates free in plasma at a concentration of 0.1–2 μM, but its levels increase locally when it is released from activated platelets. Although zinc influences many processes in haemostasis, its effect on fibrinolysis has not been thoroughly investigated. Using a fluorescent zinc-binding probe, we demonstrated that zinc binds tissue-type plasminogen activator (tPA) and plasmin with high affinity (Kd values of 0.2 μM), and surface plasmon resonance studies revealed that zinc binds fibrin with a Kd of 12.8 μM. Zinc had no effect on the affinity of plasminogen or plasmin for fibrin, but increased the affinity of tPA by two-fold. In the presence of 5 μM zinc, the catalytic efficiency of plasminogen activation by tPA was reduced by approximately two-fold, both in the absence or presence of fibrin. Zinc attenuated plasminmediated degradation of the fibrinogen alpha-chain by 43 %, but had no effect on trypsin degradation. tPA-mediated fibrin clot lysis was prolonged 2.5-fold by zinc in a concentration-dependent fashion, and tPA-mediated plasma clot lysis was attenuated by 1.5-fold. Therefore, our data indicate that zinc modulates fibrinolysis by attenuating tPAmediated plasminogen activation and plasmin-induced fibrin degradation. These findings suggest that local release of zinc by platelets attenuates fibrinolysis.

 
  • References

  • 1 Collet JP, Woodhead JL, Soria J. et al. Fibrinogen Dusart: electron microscopy of molecules, fibres and clots, and viscoelastic properties of clots. Biophys J 1996; 70: 500-510.
  • 2 Levin EG, Marzec U, Anderson J. et al. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 1984; 74: 1988-1995.
  • 3 Sappino AP, Huarte J, Vassalli JD. et al. Sites of synthesis of urokinase and tissuetype plasminogen activators in the murine kidney. J Clin Invest 1991; 87: 962-970.
  • 4 Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci 2011; 68: 785-801.
  • 5 Tubek S, Grzanka P. Tubek I. Role of zinc in haemostasis: a review Biol Trace Elem Res 2008; 121: 1-8.
  • 6 Lu J, Stewart AJ, Sadler PJ. et al. Albumin as a zinc carrier: properties of its highaffinity zinc-binding site. Biochem Soc Trans 2008; 36: 1317-1321.
  • 7 Gorodetsky R, Mou X, Blankenfeld A. et al. Platelet multielemental composition, lability, and subcellular localisation. Am J Hematol 1993; 42: 278-283.
  • 8 Whitehouse RC, Prasad AS, Rabbani PI. et al. Zinc in plasma, neutrophils, lymphocytes, and erythrocytes as determined by flameless atomic absorption spectrophotometry. Clin Chem 1982; 28: 475-480.
  • 9 Marx G, Korner G, Mou X. et al. Packaging zinc, fibrinogen, and factor XIII in platelet alpha-granules. J Cell Physiol 1993; 156: 437-442.
  • 10 Rojkjaer R, Schmaier AH. Activation of the plasma kallikrein/kinin system on endothelial cells. Proc Assoc Am Phys 1999; 111: 220-227.
  • 11 Marx G, Eldor A. The procoagulant effect of zinc on fibrin clot formation. Am J Hematol 1985; 19: 151-159.
  • 12 Marx G. Zinc binding to fibrinogen and fibrin. Arch Biochem Biophys 1988; 266: 285-288.
  • 13 Marx G, Hopmeier P. Zinc inhibits FPA release and increases fibrin turbidity. Am J Hematol 1986; 22: 347-353.
  • 14 Marx G, Hopmeier P, Gurfel D. Zinc alters fibrin ultrastructure. Thromb Haemost 1987; 57: 73-76.
  • 15 Hopmeier P, Halbmayer M, Fischer M. et al. Zinc modulates thrombin adsorption to fibrin. Thromb Res 1990; 58: 293-301.
  • 16 Fredenburgh JC, Leslie BA, Stafford AR. et al. Zn2+ mediates high affinity binding of heparin to the alphaC domain of fibrinogen. J Biol Chem 2013; 288: 29394-29402.
  • 17 Fredenburgh JC, Stafford AR, Leslie BA. et al. Bivalent binding to gammaA/ gamma’-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. J Biol Chem 2008; 283: 2470-2477.
  • 18 Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999; 274: 5201-5212.
  • 19 Kim PY, Tieu LD, Stafford AR. et al. A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J Biol Chem 2012; 287: 4652-4661.
  • 20 Stewart RJ, Fredenburgh JC, Weitz JI. Characterisation of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibri-nogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E. J Biol Chem 1998; 273: 18292-18299.
  • 21 Low CM, Zheng F, Lyuboslavsky P. et al. Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors. Proc Natl Acad Sci USA 2000; 97: 11062-11067.
  • 22 Krezel A, Wojcik J, Maciejczyk M. et al. Zn(II) complexes of glutathione disulfide: structural basis of elevated stabilities. Inorg Chem 2011; 50: 72-85.
  • 23 Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279: 13333-13339.
  • 24 Kiem J, Borberg H, Iyengar GV. et al. Elemental composition of platelets. Part II. Water content of normal human platelets and measurements of their concentrations of Cu Fe, K, and Zn by neutron activation analysis. Clin Chem 1979; 25: 705-710.
  • 25 Mahdi F, Madar ZS, Figueroa CD. et al. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99: 3585-3596.
  • 26 Stewart AJ, Blindauer CA, Sadler PJ. Plasma fatty acid levels may regulate the Zn(2+)-dependent activities of histidine-rich glycoprotein. Biochimie 2009; 91: 1518-1522.
  • 27 Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Physiol Rev 1993; 73: 79-118.
  • 28 Liu CY, Sobel JH, Weitz JI. et al. Immunologic identification of the cleavage products from the A alpha-and B beta-chains in the early stages of plasmin digestion of fibrinogen. Thromb Haemost 1986; 56: 100-106.
  • 29 Vu TT, Fredenburgh JC, Weitz JI. Zinc: an important cofactor in haemostasis and thrombosis. Thromb Haemost 2013; 109: 421-430.
  • 30 Guthans SL, Morgan WT. The interaction of zinc, nickel and cadmium with serum albumin and histidine-rich glycoprotein assessed by equilibrium dialysis and immunoadsorbent chromatography. Arch Biochem Biophys 1982; 218: 320-328.
  • 31 Foote JW, Delves HT. Albumin bound and alpha 2-macroglobulin bound zinc concentrations in the sera of healthy adults. J Clin Pathol 1984; 37: 1050-1054.
  • 32 Bax CM, Bloxam DL. Human fetal endothelial cells acquire zinc(II) from both the protein bound and nonprotein bound pools in serum. Biol Trace Elem Res 1997; 56: 255-271.
  • 33 Muthard RW, Diamond SL. Blood clots are rapidly assembled haemodynamic sensors: flow arrest triggers intraluminal thrombus contraction. Arterioscler Thromb Vasc Biol 2012; 32: 2938-2945.
  • 34 Rojkjaer R, Hasan AA, Motta G. et al. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80: 74-81.
  • 35 Siddiq MM, Tsirka SE. Modulation of zinc toxicity by tissue plasminogen activator. Mol Cell Neurosci 2004; 25: 162-171.
  • 36 Rijken DC, Groeneveld E. Isolation and functional characterisation of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3098-3102.
  • 37 Nozaki C, Vergnano AM, Filliol D. et al. Zinc alleviates pain through high-affinity binding to the NMDA receptor NR2A subunit. Nat Neurosci 2011; 14: 1017-1022.
  • 38 Tu Z, Liang J. Zinc inhibits tumor metastasis by regulating plasminogen activation. Intl J Cancer Res 2006; 02: 376-382.